fig1
![Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer](https://image.oaes.cc/e1a7b407-2293-4947-b9d6-4e49061f34a9/4059.fig.1.jpg)
Figure 1. Flow chart of the study. NSCLC: Non-small cell lung cancer; ICIs: immune checkpoint inhibitors; EGFR: epidermal growth factor receptor.
Figure 1. Flow chart of the study. NSCLC: Non-small cell lung cancer; ICIs: immune checkpoint inhibitors; EGFR: epidermal growth factor receptor.
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/